(Q38006416)

26 August 2017

title

Atomoxetine for treating ADHD symptoms in autism: a systematic review (English)

1 reference

26 August 2017

0 references

1 reference

1 reference

1

Ahmad Ghanizadeh

1 reference

26 August 2017

publication date

27 April 2012

1 reference

Journal of Attention Disorders

26 August 2017

published in

1 reference

26 August 2017

volume

17

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

635-640

1 reference

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

ADHD symptom subtypes in children with pervasive developmental disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Factor analysis on ADHD and autism spectrum disorder DSM-IV-derived items shows lack of overlap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Children with autism spectrum disorders and intellectual disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Attention-deficit/Hyperactivity Disorder in the Context of Autism Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

The status of pharmacotherapy for autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Atomoxetine treating patients with Autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Pharmacogenetic approach for a better drug treatment in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Pharmacotherapeutics of Tourette syndrome and stereotypies in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054712443154

21 January 2018

Identifiers

DOI

10.1177/1087054712443154

1 reference

26 August 2017

1 reference